Loading…

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients

Saved in:

Bibliographic Details
Published in:	British journal of haematology 2023-04, Vol.201 (1), p.162-167
Main Authors:	Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al‐Kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Eyre, Toby A., Bygrave, Ceri, Kothari, Jaimal, Basu, Supratik, Ramasamy, Karthik
Format:	Article
Language:	English
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Dexamethasone Dexamethasone - therapeutic use Frailty Hematology Humans isatuximab Multiple Myeloma - drug therapy Myeloma Neoplasm Recurrence, Local - drug therapy pomalidomide real‐world United Kingdom - epidemiology
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!